What is Leerink Partnrs’ Estimate for XENE Q1 Earnings?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Xenon Pharmaceuticals in a research report issued to clients and investors on Thursday, February 27th. Leerink Partnrs analyst M. Goodman expects that the biopharmaceutical company will earn ($0.97) per share for the quarter. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. Leerink Partnrs also issued estimates for Xenon Pharmaceuticals’ Q4 2025 earnings at ($1.23) EPS and FY2029 earnings at $2.05 EPS.

Other equities research analysts have also issued reports about the company. HC Wainwright reissued a “buy” rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research report on Monday, February 24th. William Blair reissued an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Friday. Needham & Company LLC restated a “buy” rating and issued a $60.00 price target on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a “buy” rating and a $67.00 price objective for the company. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $57.38.

Xenon Pharmaceuticals Stock Down 3.3 %

Shares of NASDAQ XENE opened at $35.79 on Monday. The stock’s 50 day moving average price is $39.22 and its two-hundred day moving average price is $40.31. Xenon Pharmaceuticals has a 52-week low of $33.27 and a 52-week high of $47.80. The stock has a market capitalization of $2.73 billion, a P/E ratio of -12.69 and a beta of 1.20.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.05.

Institutional Trading of Xenon Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Janus Henderson Group PLC lifted its holdings in shares of Xenon Pharmaceuticals by 144.2% in the third quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company’s stock valued at $100,506,000 after purchasing an additional 1,507,135 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Xenon Pharmaceuticals by 1,263.2% in the third quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company’s stock worth $38,456,000 after buying an additional 905,129 shares during the last quarter. FMR LLC boosted its position in Xenon Pharmaceuticals by 8.8% during the fourth quarter. FMR LLC now owns 7,525,290 shares of the biopharmaceutical company’s stock worth $294,991,000 after purchasing an additional 607,606 shares during the period. Boxer Capital Management LLC bought a new position in Xenon Pharmaceuticals in the 4th quarter worth $23,520,000. Finally, Stempoint Capital LP bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter worth about $14,733,000. 95.45% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Xenon Pharmaceuticals news, CFO Sherry Aulin sold 18,709 shares of the business’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ian Mortimer sold 22,468 shares of the firm’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $40.20, for a total value of $903,213.60. Following the transaction, the chief executive officer now directly owns 31,302 shares in the company, valued at $1,258,340.40. This trade represents a 41.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 57,492 shares of company stock valued at $2,334,969 in the last quarter. Company insiders own 5.52% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.